Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD81 T-cell recall responses

Blood

Volumn 121, Issue 13, 2013, Pages 2432-2439

  Zhang, Liang ^a   Bridle, Byram W ^a   Chen, Lan ^a   Pol, Jonathan ^a   Spaner, David ^b   Boudreau, Jeanette E ^c   Rosen, Allison ^a   Bassett, Jennifer D ^a   Lichty, Brian D ^a   Bramson, Jonathan L ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 33; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; IMMUNIZATION; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID ORGAN; MEMORY T LYMPHOCYTE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; SECONDARY IMMUNE RESPONSE; SPLEEN; T LYMPHOCYTE ACTIVATION; VESICULOVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS RECOMBINANT; ACCELERATION; ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL CULTURE; EVALUATION; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; METHODOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION; VACCINATION;

ACCELERATION; ADENOVIRIDAE; ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VACCINATION;

MLCS; MLOWN;

EID: 84878380056     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438481     Document Type: Article

References (47)

1. Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J. 2011; 17(5):359-371.
2. Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: Deployment in sight. Curr Opin Immunol. 2011; 23(3):377-382.
3. Schneider J, Gilbert SC, Hannan CM, et al. Induction of CD81 T cells using heterologous prime-boost immunisation strategies. Immunol Rev. 1999;170:29-38.
4. Woodland DL. Jump-starting the immune system: Prime-boosting comes of age. Trends Immunol. 2004;25(2):98-104.
5. Sigal LJ, Rock KL. Bone marrow-derived antigenpresenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J Exp Med. 2000;192(8):1143-1150.
6. Norbury CC, Malide D, Gibbs JS, et al. Visualizing priming of virus-specific CD81 T cells by infected dendritic cells in vivo. Nat Immunol. 2002;3(3): 265-271.
7. Carbone FR, Belz GT, Heath WR. Transfer of antigen between migrating and lymph noderesident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004;25(12):655-658.
8. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph noderesident dendritic cell population for efficient CTL priming. Immunity. 2006;25(1):153-162.
9. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291(5512): 2413-2417.
10. Sallusto F, Lenig D, Förster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-712.
11. Jung YW, Rutishauser RL, Joshi NS, et al. Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection. J Immunol. 2010;185(9): 5315-5325.
12. Ronchese F, Hermans IF. Killing of dendritic cells: A life cut short or a purposeful death? J Exp Med. 2001;194(5):F23-F26
13. Luketic L, Delanghe J, Sobol PT, et al. Antigen presentation by exosomes released from peptidepulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol. 2007;179(8): 5024-5032.
14. Yang J, Huck SP, McHugh RS, et al. Perforindependent elimination of dendritic cells regulates the expansion of antigen-specific CD81 T cells in vivo. Proc Natl Acad Sci USA. 2006;103(1): 147-152.
15. Wong P, Pamer EG. Feedback regulation of pathogen-specific T cell priming. Immunity. 2003; 18(4):499-511.
16. Schultze JL, Grabbe S, von Bergwelt-Baildon MS. DCs and CD40-activated B cells: Current and future avenues to cellular cancer immunotherapy. Trends Immunol. 2004;25(12):659-664.
17. Lapointe R, Bellemare-Pelletier A, Housseau F, et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63(11):2836-2843.
18. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application. Blood. 2002;99(9):3319-3325.
19. Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol. 2002;169(4):2164-2171.
20. Boudreau JE, Bridle BW, Stephenson KB, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther. 2009;17(8):1465-1472.
21. Bassett JD, Yang TC, Bernard D, et al. CD81 Tcell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood. 2011;117(4):1146-1155.
22. Oldstone MB, Tishon A, Eddleston M, et al. Vaccination to prevent persistent viral infection. J Virol. 1993;67(7):4372-4378.
23. Tomic J, White D, Shi Y, et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol. 2006;176(6): 3830-3839.
24. Boudreau J, Koshy S, Cummings D, Wan Y. Culture of myeloid dendritic cells from bone marrow precursors. J Vis Exp 2008(17):pii: 769.
25. Bridle BW, Boudreau JE, Lichty BD, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther. 2009;17(10):1814-1821.
26. Khanna KM, McNamara JT, Lefrançois L. In situ imaging of the endogenous CD8 T cell response to infection. Science. 2007;318(5847):116-120.
27. Dauner JG, Williams IR, Jacob J. Differential microenvironment localization of effector and memory CD8 T cells. J Immunol. 2008;180(1): 291-299.
28. Potsch C, Vöhringer D, Pircher H. Distinct migration patterns of naive and effector CD8 T cells in the spleen: Correlation with CCR7 receptor expression and chemokine reactivity. Eur J Immunol. 1999;29(11):3562-3570.
29. Weninger W, Crowley MA, Manjunath N, et al. Migratory properties of naive, effector, and memory CD8(1) T cells. J Exp Med. 2001;194(7): 953-966.
30. Huleatt JW, Lefrançois L. Antigen-driven induction of CD11c on intestinal intraepithelial lymphocytes and CD81 T cells in vivo. J Immunol. 1995; 154(11):5684-5693.
31. Lin Y, Roberts TJ, Sriram V, et al. Myeloid marker expression on antiviral CD81 T cells following an acute virus infection. Eur J Immunol. 2003;33(10): 2736-2743.
32. Hermans IF, Ritchie DS, Yang J, et al. CD81 T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol. 2000;164(6):3095-3101.
33. Ludewig B, Bonilla WV, Dumrese T, et al. Perforin-independent regulation of dendritic cell homeostasis by CD8(1) T cells in vivo: Implications for adaptive immunotherapy. Eur J Immunol. 2001;31(6):1772-1779.
34. Belz GT, Zhang L, Lay MD, et al. Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD81 T cell. Proc Natl Acad Sci USA. 2007;104(15):6341-6346.
35. Guarda G, Hons M, Soriano SF, et al. L-selectinnegative CCR7- effector and memory CD81 T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol. 2007;8(7):743-752.
36. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005;5(4):387-398.
37. Wong P, Lara-Tejero M, Ploss A, et al. Rapid development of T cell memory. J Immunol. 2004; 172(12):7239-7245.
38. Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430-1439.
39. Medema JP, Schuurhuis DH, Rea D, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells. J Exp Med. 2001;194(5):657-667.
40. Lovo E, Zhang M, Wang L, et al. Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol. 2012;188(3): 1057-1063.
41. Mueller SN, Jones CM, Stock AT, et al. CD41 T cells can protect APC from CTL-mediated elimination. J Immunol. 2006;176(12):7379-7384.
42. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59(1):56-58.
43. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407-1413.
44. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106(5): 539-549.
45. Brandsma JL, Shylankevich M, Su Y, et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol. 2007;81(11):5749-5758.
46. Daddario-DiCaprio KM, Geisbert TW, Ströher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment. Lancet. 2006;367(9520): 1399-1404.
47. Rose NF, Roberts A, Buonocore L, et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74(23):10903-10910.